What are the average percentage weight losses after approximately six months for the GLP‑1 receptor agonists semaglutide (2.4 mg weekly), oral semaglutide (14 mg daily), liraglutide (3 mg daily), dulaglutide (1.5 mg weekly), exenatide extended‑release (2 mg weekly), and tirzepatide (15 mg weekly)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Weight Loss Percentages Across GLP-1 Receptor Agonists

Tirzepatide 15 mg weekly produces the greatest weight loss at approximately 20.9% after 72 weeks, followed by semaglutide 2.4 mg weekly at 14.9% after 68 weeks, oral semaglutide 14 mg daily at 15.1% after 68 weeks, liraglutide 3 mg daily at 8.0% after 56 weeks, dulaglutide 1.5 mg weekly at 1.7-10% (variable), and exenatide extended-release 2 mg weekly at 4%. 1

Comparative Weight Loss at Approximately 6 Months

Highest Efficacy Agents

  • Tirzepatide 15 mg weekly: At 48 weeks, produces 22.1% weight loss (95% CI, 19.3-24.9%) with the novel agent retatrutide showing even higher efficacy 2. The FDA-approved tirzepatide demonstrates 20.9% weight loss at 72 weeks 1.

  • Semaglutide 2.4 mg subcutaneous weekly: Achieves 14.9% weight loss at 68 weeks (placebo 2.4%; difference 12.4%; 95% CI, 11.5-13.4%) in the STEP 1 trial 1. At 6 months specifically, weight reduction averages approximately 5% across multiple agents, with semaglutide showing comparable effects to liraglutide and exenatide at this timepoint 3.

  • Oral semaglutide 14 mg daily: Produces 15.1% weight loss versus 2.4% for placebo at 68 weeks 1. High-dose oral semaglutide shows mean difference of -11.6% compared to placebo 4.

Moderate Efficacy Agents

  • Liraglutide 3 mg daily: Achieves 8.0% mean weight loss at 56 weeks (difference 5.4%; 95% CI, 5.8-5.0%) 1. At 26 weeks, produces up to 5.8% weight loss (95% CI, 3.6-8.0%) 2. Individual studies show 15.9-25.2% of patients achieve ≥10% weight reduction 5.

  • Dulaglutide 1.5 mg weekly: Shows highly variable results with 1.7-10% of patients achieving ≥10% weight reduction across trials 5. Mean weight loss is approximately 4.03 kg 6. The FDA label does not specify percentage weight loss outcomes for obesity treatment 7.

Lower Efficacy Agents

  • Exenatide extended-release 2 mg weekly: Only 4% of patients achieve ≥10% weight reduction 5. Mean weight loss is approximately 1.9 kg 6.

Key Clinical Considerations

Dose-Response Relationships

The evidence demonstrates clear dose-dependent effects. For tirzepatide, the 15 mg dose produces 20.9% weight loss compared to 19.5% for 10 mg and 15.0% for 5 mg 1. This hierarchical response pattern is consistent across GLP-1 receptor agonists.

Time to Maximum Effect

Weight loss is not linear. Semaglutide shows approximately 5% reduction at 6 months but reaches 13.9-14.9% by 68 weeks 2, 3. Real-world data confirms that tirzepatide produces faster monthly weight-loss velocity (2.54%) compared to semaglutide (2.18%) 8.

Real-World Versus Trial Data

Critical caveat: Real-world effectiveness differs substantially from trial efficacy. In Danish primary care, only 48% of patients remained on semaglutide at 12 months, with 40% using ≤1.0 mg/week (below target dose) 9. Despite this, those who continued treatment achieved -13.6% (95% CI -15.0 to -12.2%) weight loss 9.

Network Meta-Analysis Findings

When comparing agents head-to-head through network meta-analysis, tirzepatide 10 mg and 15 mg weekly result in significantly more weight loss than semaglutide 2.4 mg weekly, which in turn outperforms liraglutide 3 mg daily 10. The mean difference between semaglutide and liraglutide is -6.08 kg (95% CI -8.40, -3.75), while tirzepatide exceeds semaglutide by -3.78 kg (95% CI -5.52, -2.04) 6.

Safety Profile Across Agents

All GLP-1 receptor agonists trigger more gastrointestinal adverse events than placebo (47-84% versus 13-63%), predominantly nausea, vomiting, diarrhea, and constipation 2. However, tirzepatide shows lower prevalence of gastrointestinal and systemic adverse events compared to semaglutide in real-world AI-enabled curation of clinical notes 8. Treatment discontinuation due to adverse events ranges from 0-26% across agents 2.

Demographic Variations

Important consideration: Response varies significantly by demographics. Women show higher representation among high responders (≥15% weight loss), while White patients are overrepresented among high responders and Black and Hispanic patients are overrepresented in the minimal weight-loss group (<5%) for both tirzepatide and semaglutide 8.

Quality of Weight Loss

GLP-1 receptor agonists produce "quality" weight loss through selective fat mass reduction with relative preservation of lean tissue. At 3 months, mean body weight decreases by approximately 9% with marked reductions in fat mass and visceral adipose tissue, while lean mass remains largely preserved 3.

Durability Concerns

Major pitfall: Weight regain occurs rapidly after discontinuation. After 68 weeks of semaglutide treatment, participants regained 11.6% of lost weight over an additional 52 weeks off medication 1. In the STEP 4 trial, transitioning from semaglutide to placebo after 20 weeks resulted in 6.9% weight regain over 48 weeks 1, indicating lifelong treatment necessity.

References

Related Questions

What is the recommended management protocol for weight loss using glucagon‑like peptide‑1 (GLP‑1) receptor agonists in adults?
What were the efficacy outcomes and dosing protocol of the 68‑week semaglutide 2.4 mg (subcutaneous) weight‑loss trial in adults with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities)?
A patient allergic to dulaglutide, exenatide, and semaglutide is currently on Humalog (insulin lispro); is it safe to switch them to Novolog (insulin aspart)?
What are alternative therapies to Trulicity (dulaglutide) for an adult with type 2 diabetes?
In a 59-year-old woman with weight 152 lb, BMI 29, hyperlipidemia, obstructive sleep apnea, and prior cerebrovascular accident, whose weight loss has plateaued on Wegovy (semaglutide) 2.4 mg weekly, can the dose be increased to Wegovy 7.2 mg weekly?
Which GLP‑1 receptor agonist has the best overall tolerability?
How is hypocalcemia classified by serum calcium concentration, clinical severity, and underlying cause?
How is the Bronchiectasis Severity Index (BSI) calculated at diagnosis to stratify risk of future complications?
What are the causes of thrombocytosis and leukocytosis in a 55‑year‑old woman with low testosterone, normal pituitary function, normal C‑reactive protein, normal glycated hemoglobin, and dyslipidemia?
What are the expected weight loss percentages for each oral orforglipron dose (6 mg, 12 mg, 24 mg, 36 mg) over approximately six months?
What is the appropriate evaluation and management for a patient presenting with headache and transient blurring of vision?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.